Image credit- billboard.com
Qiagen has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven Qiagen chemistries.
Qiagen has agreed to acquire all shares of STAT-Dx for approximately $147 million in cash and additional payments of up to about $44 million based on the achievement of regulatory and commercial milestones. The acquisition is expected to be completed in the second quarter of 2018 and funded from existing cash reserves.
The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with high-quality Qiagen sample and assay technologies developed under a long-standing collaboration between the companies. QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immuno-assays.
